Biofusion represents a great opportunity for investors to play an integral role in the development of world class innovation and we seek to create value for our shareholders through the effective, intelligent management of this valuable IP.
The following information is provided pursuant to AIM Rule 26:
- Biofusion is incorporated in London and its main area of operation is the United Kingdom.
- We are an Alternative Investment Market (AIM) registered company listed under the code BFN.
- All BFN shares are freely tradable.
Date of last AIM Rule 26 update: 23 April 2008